Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
The closing price of Soleno Therapeutics Inc (NASDAQ: SLNO) was $41.54 for the day, down -3.40% from the previous closing price of $43.0. In other words, the price has decreased by -$3.40 from its previous closing price. On the day, 3.47 million shares were traded. SLNO stock price reached its highest trading level at $45.455 during the session, while it also had its lowest trading level at $40.0.
Ratios:
Our analysis of SLNO’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 15.88 and its Current Ratio is at 16.08. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In the most recent recommendation for this company, Wolfe Research on November 18, 2025, initiated with a Outperform rating and assigned the stock a target price of $75.
On October 07, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $125.
On August 20, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $123.Wells Fargo initiated its Overweight rating on August 20, 2025, with a $123 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 11 ’25 when Abingworth Bioventures VII LP bought 1,347,522 shares for $82.15 per share.
Hirano Patricia C sold 3,830 shares of SLNO for $316,971 on Jul 01 ’25. The insider now owns 13,206 shares after completing the transaction at $82.76 per share. On Jul 01 ’25, another insider, PATRICIA HIRANO, who serves as the Officer of the company, bought 3,830 shares for $82.76 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLNO now has a Market Capitalization of 2231114496 and an Enterprise Value of 1784843392. For the stock, the TTM Price-to-Sale (P/S) ratio is 22.61 while its Price-to-Book (P/B) ratio in mrq is 4.51. Its current Enterprise Value per Revenue stands at 18.088 whereas that against EBITDA is -21.698.
Stock Price History:
The Beta on a monthly basis for SLNO is -3.16, which has changed by 0.010813355 over the last 52 weeks, in comparison to a change of 0.19226205 over the same period for the S&P500. Over the past 52 weeks, SLNO has reached a high of $90.32, while it has fallen to a 52-week low of $41.50. The 50-Day Moving Average of the stock is -15.90%, while the 200-Day Moving Average is calculated to be -38.08%.
Shares Statistics:
SLNO traded an average of 1.75M shares per day over the past three months and 1601050 shares per day over the past ten days. A total of 53.70M shares are outstanding, with a floating share count of 49.48M. Insiders hold about 7.87% of the company’s shares, while institutions hold 117.93% stake in the company. Shares short for SLNO as of 1767139200 were 10928578 with a Short Ratio of 6.24, compared to 1764288000 on 9093766. Therefore, it implies a Short% of Shares Outstanding of 10928578 and a Short% of Float of 23.200001.
Earnings Estimates
The performance of Soleno Therapeutics Inc (SLNO) in the stock market is under the watchful eye of 13.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.71, with high estimates of $1.15 and low estimates of $0.23.
Analysts are recommending an EPS of between $0.74 and -$0.24 for the fiscal current year, implying an average EPS of $0.14. EPS for the following year is $4.08, with 13.0 analysts recommending between $5.76 and $1.78.
Revenue Estimates
For the next quarter, 11 analysts are estimating revenue of $91.27M. There is a high estimate of $115.95M for the next quarter, whereas the lowest estimate is $73.8M. Based on 11 analysts’ estimates, the company’s revenue will be $465.07M in the next fiscal year. The high estimate is $563.14M and the low estimate is $351.6M.
